WuXi Biologics (Cayman) Inc 02269
News
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
WuXi AppTec Shares Rally Amid Sectorwide Gains After Tech Selloff, China Policy Support
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
WuXi Biologics Plans to Buy Back Up to US$400 Million of Shares
Chinese Pharma Stocks Fall on Potential U.S. Restrictions on Drugs

